CDMO · Avid Bioservices, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 | Q2 '22 | Q1 '23 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.48M | $40.17M | $25.39M | $33.81M | $37.73M | - | $38.02M | $34.76M | $36.69M | $31.51M |
| Cost of Revenue | $35.53M | $34.46M | $30.06M | $31.43M | $33.63M | - | $28.19M | $30.61M | $27.57M | $22.42M |
| Gross Profit | ($2.04M) | $5.71M | ($4.67M) | $2.38M | $4.10M | - | $9.82M | $4.15M | $9.12M | $9.09M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $10.59M | $8.17M | $6.56M | $6.38M | $6.26M | - | $7.11M | $6.83M | $6.38M | $5.82M |
| Total Operating Expenses | $10.59M | $8.17M | $6.56M | $6.38M | $6.26M | - | $7.11M | $6.83M | $4.46M | $5.82M |
| D&A | $4.00M | $2.82M | $2.80M | $2.80M | $2.65M | - | $1.90M | $1.80M | $1.59M | $1.00M |
| Operating Income | ($12.63M) | ($2.46M) | ($11.22M) | ($4.00M) | ($2.16M) | - | $2.72M | ($2.68M) | $2.73M | $3.27M |
| Interest Expense | $3.28M | $2.45M | $805.0K | $875.0K | $775.0K | - | $620.0K | $703.0K | $518.0K | $718.0K |
| Income Tax | $0 | $0 | ($2.38M) | ($1.05M) | ($587.0K) | - | $2.07M | $0 | $703.0K | - |
| Net Income | ($17.41M) | ($5.53M) | ($9.51M) | ($6.01M) | ($2.09M) | - | $461.0K | ($1.16M) | $1.56M | $2.25M |
| EPS - Basic | ($0.27) | ($0.09) | ($0.15) | ($0.09) | ($0.03) | - | $0.01 | ($0.02) | $0.03 | $0.04 |
| EPS - Diluted | ($0.27) | ($0.09) | ($0.15) | ($0.09) | ($0.03) | - | $0.01 | ($0.02) | $0.02 | $0.04 |
Balance Sheet
| Line item | Q2 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 | Q2 '22 | Q1 '23 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.41M | $33.38M | $38.11M | $30.71M | $24.90M | $38.54M | $59.92M | $77.29M | $115.14M | $149.96M |
| Accounts Receivable | $18.41M | $20.96M | $16.64M | $18.54M | $16.21M | $18.30M | $14.83M | $20.58M | $25.95M | $28.01M |
| Inventory | $28.07M | $29.20M | $30.38M | $34.57M | $40.87M | $43.91M | $45.10M | $39.06M | $30.35M | $21.05M |
| Accounts Payable | $9.25M | $20.00M | $20.67M | $19.51M | $22.81M | $24.59M | $36.39M | $23.33M | $30.46M | $6.46M |
| Current Assets | $96.50M | $103.62M | $104.00M | $103.59M | $98.32M | $112.45M | $132.34M | $145.94M | $180.63M | $203.49M |
| Total Assets | $323.48M | $334.64M | $336.56M | $455.23M | $442.34M | $451.05M | $450.43M | $441.85M | $451.22M | $314.10M |
| Current Liabilities | $74.16M | $71.08M | $70.57M | $222.89M | $64.06M | $73.71M | $87.32M | $82.38M | $93.34M | $77.30M |
| Long-term Debt | $52.87M | $53.57M | $54.24M | $54.91M | $48.59M | $49.14M | $40.91M | $41.81M | $42.70M | $44.03M |
| Total Liabilities | $278.67M | $276.01M | $275.67M | $275.06M | $251.74M | $261.58M | $265.04M | $260.65M | $272.22M | $257.52M |
| Stockholders' Equity | $44.81M | $58.64M | $60.89M | $180.17M | $190.60M | $189.47M | $185.40M | $181.19M | $179.00M | $56.58M |
| Retained Earnings | ($594.81M) | ($577.40M) | ($571.87M) | ($448.77M) | ($432.91M) | ($430.82M) | ($430.51M) | ($430.97M) | ($429.81M) | ($546.98M) |
Cash Flow
| Line item | Q2 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 | Q2 '22 | Q1 '23 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($3.68M) | - | - | ($278.0K) | - | - | - | ($5.03M) | - |
| Investing Cash Flow | - | ($1.31M) | - | - | ($14.11M) | - | - | - | ($6.92M) | - |
| Financing Cash Flow | - | $266.0K | - | - | $748.0K | - | - | - | $929.0K | - |
| CapEx | - | $1.31M | - | - | $14.11M | - | - | - | $6.92M | - |
| Free Cash Flow | - | ($4.99M) | - | - | ($14.39M) | - | - | - | ($11.96M) | - |
Ratios
| Metric | Q2 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 | Q2 '22 | Q1 '23 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -6.1% | 14.2% | -18.4% | 7.0% | 10.9% | - | 25.8% | 11.9% | 24.8% | 28.8% |
| Operating margin | -37.7% | -6.1% | -44.2% | -11.8% | -5.7% | - | 7.1% | -7.7% | 7.5% | 10.4% |
| EBITDA margin | -25.8% | 0.9% | -33.2% | -3.5% | 1.3% | - | 12.1% | -2.5% | 11.8% | 13.5% |
| Net margin | -52.0% | -13.8% | -37.4% | -17.8% | -5.5% | - | 1.2% | -3.3% | 4.3% | 7.1% |
| Free cash flow margin | - | -12.4% | - | - | -38.1% | - | - | - | -32.6% | - |
| FCF / Net income | - | 0.90 | - | - | 6.88 | - | - | - | -7.65 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 31.6% | 20.3% | 25.8% | 18.9% | 16.6% | - | 18.7% | 19.7% | 17.4% | 18.5% |
| Effective tax rate | - | - | - | - | - | - | 81.8% | - | 31.0% | - |
| Return on assets | -5.4% | -1.7% | -2.8% | -1.3% | -0.5% | - | 0.1% | -0.3% | 0.3% | 0.7% |
| Return on equity | -38.8% | -9.4% | -15.6% | -3.3% | -1.1% | - | 0.2% | -0.6% | 0.9% | 4.0% |
| Return on invested capital | -10.2% | -1.7% | -7.7% | -1.3% | -0.7% | - | 0.6% | -1.0% | 0.9% | - |
| Liquidity | ||||||||||
| Current ratio | 1.30 | 1.46 | 1.47 | 0.46 | 1.53 | 1.53 | 1.52 | 1.77 | 1.94 | 2.63 |
| Quick ratio | 0.92 | 1.05 | 1.04 | 0.31 | 0.90 | 0.93 | 1.00 | 1.30 | 1.61 | 2.36 |
| Cash ratio | 0.45 | 0.47 | 0.54 | 0.14 | 0.39 | 0.52 | 0.69 | 0.94 | 1.23 | 1.94 |
| Leverage | ||||||||||
| Debt / Equity | 1.18 | 0.91 | 0.89 | 0.30 | 0.25 | 0.26 | 0.22 | 0.23 | 0.24 | 0.78 |
| Debt / Assets | 0.16 | 0.16 | 0.16 | 0.12 | 0.11 | 0.11 | 0.09 | 0.09 | 0.09 | 0.14 |
| Debt / EBITDA | - | 145.56 | - | - | 99.99 | - | 8.86 | - | 9.87 | 10.31 |
| Interest coverage | -3.9x | -1.0x | -13.9x | -4.6x | -2.8x | - | 4.4x | -3.8x | 5.3x | 4.6x |
| Equity multiplier | 7.22 | 5.71 | 5.53 | 2.53 | 2.32 | 2.38 | 2.43 | 2.44 | 2.52 | 5.55 |
| Liabilities / Assets | 0.86 | 0.82 | 0.82 | 0.60 | 0.57 | 0.58 | 0.59 | 0.59 | 0.60 | 0.82 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | 0.12 | 0.08 | 0.07 | 0.09 | - | 0.08 | 0.08 | 0.08 | 0.10 |
| Inventory turnover | 1.27 | 1.18 | 0.99 | 0.91 | 0.82 | - | 0.63 | 0.78 | 0.91 | 1.06 |
| Days sales outstanding | 201d | 190d | 239d | 200d | 157d | - | 142d | 216d | 258d | 324d |
| Days inventory outstanding | 288d | 309d | 369d | 401d | 444d | - | 584d | 466d | 402d | 343d |
| Days payable outstanding | 95d | 212d | 251d | 227d | 248d | - | 471d | 278d | 403d | 105d |
| Cash conversion cycle | 394d | 288d | 357d | 375d | 353d | - | 255d | 404d | 257d | 562d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 31.8% | 6.5% | - | -11.1% | 2.8% | - | 20.7% | 65.0% | - | 44.5% |
| Revenue CAGR (3y) | -1.2% | - | 6.4% | 15.7% | 7.0% | - | 40.9% | 50.6% | 34.0% | 31.7% |
| Revenue CAGR (5y) | 12.8% | 21.4% | 20.1% | 19.7% | 24.5% | - | - | 8.3% | - | 24.0% |
| Gross profit growth (YoY) | 56.2% | 39.3% | - | -75.7% | -55.0% | - | 8.1% | -35.4% | - | 46.5% |
| Operating income growth (YoY) | -12.6% | -13.5% | - | - | - | - | -16.9% | - | - | 49.7% |
| Net income growth (YoY) | -83.0% | -164.4% | - | - | - | - | -79.5% | - | - | 1.9% |
| EPS growth (YoY) | -80.0% | -200.0% | - | - | - | - | -75.0% | 33.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 65.3% | - | - | -20.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -26.4% | -69.2% | -67.9% | -2.8% | 6.5% | 4.6% | 227.7% | 133.1% | - | -33.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-04-30.
Product / service
$139.91M totalManufacturing Revenue$119.34M · 85.3%
Process Development Revenue$20.57M · 14.7%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Avid Bioservices against the 5 most active filers in the same SIC group.